Cell death, Immunity and Therapeutic Innovation

This group belongs to the UMR 1030 - Molecular radiotherapy and therapeutic innovations

Research topics

With the ambition of optimizing the efficacy of anticancer treatments (in particular radiotherapy), we are developing a research program that aims at identifying and characterizing the mechanisms of anticancer response at genetic, metabolic as well as immunological levels.

Villejuif, le 30 novembre 2020

Lab members

• Geoerger Birgit, MD, PhD, HDR, PH IGR, physician-scientists/médecin-chercheur
• Gaspar Nathalie, MD, PhD, PH IGR, physician-scientists/médecin-chercheur, lead osteosarcoma group
• Salmon Jérome, PhD, Viro-Immunology, researcher/chercheur
• Marchais Antonin, PhD, Bioinformatics, researcher/chercheur                
• Dessen Philippe, PhD, DR1 CNRS, Bioinformatics, researcher/chercheur (Emeritus)
• Harttrampf Anne Catherine, MD, PhD, physician-scientists/médecin-chercheur

Major publications

1. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Handgretinger R, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy M, Cohn S, Pathiraja K, Diede S, Ebbinghaus S, Pinto N. Phase 1/2 KEYNOTE-051 study of pembrolizumab in pediatric patients with advanced melanoma or a PD-L1+ advanced, relapsed or refractory solid tumor or lymphoma. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. PMID:31812554

Pediatric Precision Medicine and Experimental Therapeutics

This group belongs to the UMR 1015 "Tumour Immunology and anti-cancer immunotherapy".

The aim of our group is to develop new innovative therapies for children with advanced cancers through our clinical precision cancer medicine trials, with one group focusing on osteosarcoma classification and development of new innovative adapted therapies in children, adolescent and young adults.

Contact

ORL

01 42 11 56 88

Chirurgie reconstructrice

01 42 11 65 36

Oncologie

01 42 11 46 05